Hepatitis B Immune Globulin
drug drugOn this page
Also known as HepabulinHepatitis b immune globulin humanHepatitis b immunoglobulinHuman hepatitis b immunoglobulinHuman hepatitis-b immunoglobulinHyperhep bHyperhep b s/dImmunogamLiberim hbZutectra
Summary
Hepatitis B Immune Globulin (CHEMBL2108512) is an approved unknown (ATC J06BB04); indicated across 4 conditions including hepatitis b virus infection and chronic hepatitis b virus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: J06BB04
- Indications: 4 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108512 |
| Name | Hepatitis B Immune Globulin |
| Type | Unknown |
| Max phase | 4 |
| ATC | J06BB04 |
Also known as: Hepabulin, Hepatitis b immune globulin, Hepatitis b immune globulin human, Hepatitis b immunoglobulin, Human hepatitis b immunoglobulin, Human hepatitis-b immunoglobulin, Hyperhep b, Hyperhep b s/d, Immunogam, Liberim hb, Zutectra, HEPATITIS B IMMUNE GLOBULIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| hepatitis B virus infection | 4 | MONDO:0005344 | EFO:0004197 |
| chronic hepatitis B virus infection | 4 | MONDO:0005366 | EFO:0004239 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01131065 | PHASE3 | COMPLETED | Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients |
| NCT01856413 | PHASE3 | COMPLETED | A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant |
| NCT05404919 | PHASE2 | WITHDRAWN | Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates |
| NCT02312531 | Not specified | COMPLETED | Prevention for Mother-to-infant Transmission of HBV |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: hepatitis B virus infection, chronic hepatitis B virus infection